Clinical Trials Directory

Trials / Terminated

TerminatedNCT00206206

Evaluation of an ICU Hyperglycemia Protocol Using Insulin Aspart

Evaluation of an ICU Hyperglycemia Protocol Using Insulin Aspart.

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
235 (planned)
Sponsor
Atlantic Health System · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

In response to the evidence supporting "tight" glucose control (70 - 110) in the critical care setting, the MMH ICU developed a protocol utilizing regular intravenous insulin. This protocol was initiated in 2002. Monitoring of the data collected revealed effective glycemic control when this protocol was used. However, limited utilization has led to overall ineffective glycemic control in this ICU. The poor utilization is largely due to a general reluctance of physicians to start their patients on an intravenous insulin infusion. As contributing to this poor compliance is the "open" nature of the ICU. The MMH ICU is an "open" ICU, meaning that many physicians across multiple subspecialties admit to this unit. Approaches to controlling hyperglycemia vary greatly, depending largely upon the treating physician. In an attempt to improve overall glycemic control in this "open" ICU, the Subcutaneaous Insulin Aspart Hyperglycemia Protocol (SIAP) was developed which incorporates a subcutaneous insulin aspart regimen that triggers the use of a regular insulin infusion protocol when the SIAP is not adequately controlling the patient's blood glucose. This study aims to evaluate 1) the effect the SIAP on overall glycemic control in the ICU, 2) the effectiveness that the SIAP has on controlling blood glucose as compared with past practices using regular insulin, and 3) the effect the SIAP has on patient complications and outcomes in the MMH ICU.

Conditions

Interventions

TypeNameDescription
PROCEDUREHyperglycemia Protocol Procedure

Timeline

Start date
2005-07-01
First posted
2005-09-21
Last updated
2006-02-07

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00206206. Inclusion in this directory is not an endorsement.